These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 32274757)

  • 1. Altered Proteostasis in Neurodegenerative Tauopathies.
    Papanikolopoulou K; Skoulakis EMC
    Adv Exp Med Biol; 2020; 1233():177-194. PubMed ID: 32274757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frontotemporal dementia with tau pathology.
    Gasparini L; Terni B; Spillantini MG
    Neurodegener Dis; 2007; 4(2-3):236-53. PubMed ID: 17596718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.
    Strang KH; Croft CL; Sorrentino ZA; Chakrabarty P; Golde TE; Giasson BI
    J Biol Chem; 2018 Feb; 293(7):2408-2421. PubMed ID: 29259137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau, tau kinases, and tauopathies: An updated overview.
    Montalto G; Ricciarelli R
    Biofactors; 2023; 49(3):502-511. PubMed ID: 36688478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau pathology in Alzheimer disease and other tauopathies.
    Iqbal K; Alonso Adel C; Chen S; Chohan MO; El-Akkad E; Gong CX; Khatoon S; Li B; Liu F; Rahman A; Tanimukai H; Grundke-Iqbal I
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):198-210. PubMed ID: 15615638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tauopathies and tau oligomers.
    Takashima A
    J Alzheimers Dis; 2013; 37(3):565-8. PubMed ID: 23948895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular degradation of misfolded tau protein induced by geldanamycin is associated with activation of proteasome.
    Opattova A; Filipcik P; Cente M; Novak M
    J Alzheimers Dis; 2013; 33(2):339-48. PubMed ID: 22936006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of tau-induced neurodegeneration.
    Iqbal K; Liu F; Gong CX; Alonso Adel C; Grundke-Iqbal I
    Acta Neuropathol; 2009 Jul; 118(1):53-69. PubMed ID: 19184068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies.
    Silva MC; Haggarty SJ
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurofibrillary tangles mediated human neuronal tauopathies: insights from fly models.
    Sarkar S
    J Genet; 2018 Jul; 97(3):783-793. PubMed ID: 30027909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo.
    Wang P; Joberty G; Buist A; Vanoosthuyse A; Stancu IC; Vasconcelos B; Pierrot N; Faelth-Savitski M; Kienlen-Campard P; Octave JN; Bantscheff M; Drewes G; Moechars D; Dewachter I
    Acta Neuropathol; 2017 May; 133(5):731-749. PubMed ID: 28083634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel drugs affecting tau behavior in the treatment of Alzheimer's disease and tauopathies.
    Navarrete LP; Pérez P; Morales I; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):678-85. PubMed ID: 21605038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted downregulation of dMyc restricts neurofibrillary tangles mediated pathogenesis of human neuronal tauopathies in Drosophila.
    Chanu SI; Sarkar S
    Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2111-2119. PubMed ID: 28529046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knockin' on heaven's door: Molecular mechanisms of neuronal tau uptake.
    De La-Rocque S; Moretto E; Butnaru I; Schiavo G
    J Neurochem; 2021 Mar; 156(5):563-588. PubMed ID: 32770783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies.
    Caccamo A; Magrì A; Medina DX; Wisely EV; López-Aranda MF; Silva AJ; Oddo S
    Aging Cell; 2013 Jun; 12(3):370-80. PubMed ID: 23425014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dephosphorylation Targeting Chimaera (DEPTAC): Targeting Tau Proteins in Tauopathies.
    Soumbasis A; Eldeeb MA; Ragheb MA; Zorca CE
    Curr Protein Pept Sci; 2022; 23(3):129-132. PubMed ID: 35598241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
    Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
    Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.